Trinity Biotech reported 95 percent AGM support for Trinity Biotech stock

Published on 10/16/2026 at 00:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-quarter 2026 revenue rose 43 percent year over year to USD 10.8 million. RedChip covers Trinity Biotech stock after margin reached 35.4 percent.

AGM approval and operating progress

Shareholders approved Trinity Biotech resolutions with at least 95 percent support on September 30, 2026.
First-quarter 2026 revenue rose 43 percent year over year to USD 10.8 million.
Trinity Biotech had a USD 160.6 million market capitalization as of October 15, 2026.

TRIB, US8964385046, Illustration mit AI erstellt.

Trinity Biotech plc (ISIN US8964385046) reported that every resolution at its annual general meeting received at least 95 percent support. The filing dated October 5, 2026 covered the meeting held on September 30, 2026, including the reappointment of Grant Thornton as auditor and Dr Andrew Omidvar as a director, according to StockTitan.

Approval follows a volatile year

The vote gives the board continuity while Trinity works through a business transition spanning diagnostics, continuous glucose monitoring and liquid cooling. The company describes itself as a commercial-stage biotechnology business serving diabetes management and human diagnostics, with products sold in more than 100 countries, according to its Trinity Biotech investor-relations page.

The recent chronology is clear. On August 14, 2026, Trinity secured an additional USD 7.0 million investment from Perceptive Advisors, a transaction listed by StockTitan. Shareholders then held the annual meeting on September 30, 2026, before the company filed the results on October 5, 2026 with minimum approval of 95 percent.

What does the operating shift mean?

The first-quarter 2026 figures point to a measurable improvement in operating execution. RedChip said revenue rose 43 percent year over year to USD 10.8 million, while gross margin increased to 35.4 percent from 25.2 percent. The same update said Trinity had orders for over 2 million TrinScreen HIV tests, giving the diagnostics business a concrete volume marker.

That progress is set against a difficult financial base. The latest standardized financial data show USD 11.1 million of revenue and a USD 17.5 million net loss in the fourth quarter of 2025. The comparison makes the margin trend important, but it also leaves commercialization and financing as central execution issues.

Small valuation, large execution gap

Trinity Biotech had a market capitalization of USD 160.6 million as of October 15, 2026, while its Nasdaq quote was last at USD 7.93 on October 15, 2026 at 4:00 p.m. ET. The same market snapshot placed the 52-week range at USD 5.01 to USD 52.50. The broad range underlines how much investor expectations can change around a small biotechnology issuer.

The stock's next test is whether the diagnostics recovery and newer CGM and Trinovium projects convert into repeatable revenue. The AGM result removes one governance question, while the first-quarter margin data provide a more direct operating measure for the next report.

Trinity Biotech was last quoted at USD 7.93 on Nasdaq on October 15, 2026 at 4:00 p.m. ET.